Lucid Diagnostics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2.98	2.43	0.38	0.5	0	0
Revenue Growth (YoY)	370.50%	544.03%	-24.60%	-	-	-
Cost of Revenue	6.3	5.98	3.61	0.59	0	0
Gross Profit	-3.31	-3.55	-3.24	-0.09	0	0
Selling, General & Admin	32.9	35.66	40.11	18.04	2.84	0.96
Research & Development	6.86	7.25	11.26	9.3	5.44	3.46
Other Operating Expenses	1.89	2.02	1.65	0	0	0
Operating Expenses	41.64	44.93	53.01	27.33	8.28	4.42
Operating Income	-44.96	-48.48	-56.25	-27.42	-8.28	-4.42
Interest Expense / Income	0.4	0.42	0.01	0.66	0	0
Other Expense / Income	1.68	3.77	-0.09	-	-	-
Pretax Income	-47.03	-52.67	-56.17	-28.08	-8.28	-4.42
Net Income	-47.03	-52.67	-56.17	-28.08	-8.28	-4.42
Preferred Dividends	7.5	0	0	0	0	0
Shares Outstanding (Basic)	45	42	36	19	14	10
Shares Outstanding (Diluted)	45	42	36	19	14	10
Shares Change	9.87%	15.44%	94.44%	31.81%	41.14%	-
EPS (Basic)	-1.26	-1.26	-1.55	-1.51	-0.59	-0.44
EPS (Diluted)	-1.26	-1.26	-1.55	-1.51	-0.59	-0.44
Free Cash Flow	-38.63	-33.04	-30.59	-18.53	-5.63	-2.36
Free Cash Flow Per Share	-0.86	-0.79	-0.85	-1.00	-0.40	-0.24
Gross Margin	-111.06%	-146.25%	-858.62%	-17.00%	-	-
Operating Margin	-1507.11%	-1996.79%	-14920.69%	-5483.80%	-	-
Profit Margin	-1827.92%	-2169.11%	-14899.47%	-5615.60%	-	-
Free Cash Flow Margin	-1294.84%	-1360.71%	-8114.85%	-3706.00%	-	-
EBITDA	-44.25	-49.75	-54.23	-27.42	-8.28	-4.42
EBITDA Margin	-1483.34%	-2049.05%	-14383.82%	-5483.00%	-	-
Depreciation & Amortization	2.39	2.5	1.94	0	0	0
EBIT	-46.64	-52.25	-56.16	-27.42	-8.28	-4.42
EBIT Margin	-1563.39%	-2151.98%	-14897.35%	-5483.80%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).